<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62565">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291432</url>
  </required_header>
  <id_info>
    <org_study_id>13-11</org_study_id>
    <nct_id>NCT02291432</nct_id>
  </id_info>
  <brief_title>Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery</brief_title>
  <official_title>Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook</source>
  <brief_summary>
    <textblock>
      To study the safety of autologous muscle-derived cells (AMDC) for the treatment of male
      stress urinary incontinence (SUI) for patients that have undergone prior prostate surgery.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of product-related serious adverse events</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of product-related, biopsy procedure-related, and injection procedure-related adverse events</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of post-void residual urine</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of urine leakage</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change is patient-reported quality of life assessed by a questionnaire</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Urinary Incontinence</condition>
  <condition>Stress</condition>
  <condition>Urination Disorders</condition>
  <condition>Urologic Diseases</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <condition>Urological Manifestations</condition>
  <arm_group>
    <arm_group_label>AMDC-USR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cell treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous muscle-derived cells (AMDC)</intervention_name>
    <description>Cell treatment</description>
    <arm_group_label>AMDC-USR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, at least 18 years old, with primary symptoms of SUI following prostate surgery,

          -  Patient has undergone prostate surgery but has not undergone radiation therapy,
             cryotherapy, or high-intensity focused ultrasound of the prostate,

          -  SUI severity should be â‰¥10 g and &lt;400 g of urine leakage over 24 hours,

          -  Patient has failed to achieve acceptable resolution of SUI symptoms following prior
             therapy.

        Exclusion Criteria:

          -  Symptoms of only urge urinary incontinence,

          -  Symptoms of stress urinary incontinence prior to prostate surgery,

          -  Routinely has more than 2 episodes of awakening to void during normal sleeping hours,

          -  Compromised immune system due to disease state, chronic corticosteroid use, or other
             immunosuppressive therapy,

          -  Previously treated with a periurethral balloon or adjustable sling for urinary
             incontinence,

          -  Symptoms of overflow incontinence

          -  Additional medical restrictions as specified in the Clinical Investigation Plan,

          -  Additional anatomical restrictions as specified in the Clinical Investigation Plan.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Peters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beaumont Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKay Urology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 17, 2017</lastchanged_date>
  <firstreceived_date>November 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Urination Disorders</mesh_term>
    <mesh_term>Urological Manifestations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
